Skip to main content

Publications

featured publications

  • Re: Assessment of PD-L1, TROP2, and NECTIN-4 Expression in Penile Squamous Cell Carcinoma.

    European urology

    Authors: Johannes Linxweiler, Niklas Klümper, Jan Mink, Markus Eckstein, Kerstin Junker

  • Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.

    Lung cancer (Amsterdam, Netherlands)

    Authors: Jonas Saal, Tobias Bald, Markus Eckstein, Damian J Ralser, Peter Brossart, Jörg Ellinger, Michael Hölzel, Niklas Klümper

  • Expression of the microtubule-associated protein 2 (MAP2) as a potential independent prognostic marker in prostate cancer.

    Journal of cancer research and clinical oncology

    Authors: Johannes Stein, Eliana Krappe, Anika Kremer, Marcus V Cronauer, Markus Essler, Alexander Cox, Niklas Klümper, Philipp Krausewitz, Jörg Ellinger, Manuel Ritter, Glen Kristiansen, Michael Majores

  • Ring Finger Protein 34 (RNF34) as a Prognostic Biomarker for Clear Cell Renal Cell Carcinoma.

    Cureus

    Authors: Johannes Stein, Niklas Klümper, Pirmin Zöhrer, Thomas Büttner, Philipp Krausewitz, Manuel Ritter, Glen Kristiansen, Marieta Toma, Jörg Ellinger, Alexander Cox

  • Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach.

    Cancers

    Authors: Thomas Büttner, Dimo Dietrich, Romina Zarbl, Niklas Klümper, Jörg Ellinger, Philipp Krausewitz, Manuel Ritter

  • Hypermethylated SHOX2 in circulating cell-free DNA post renal cell carcinoma surgery as TNM-independent biomarker for recurrence risk.

    American journal of translational research

    Authors: Thomas Büttner, Romina Zarbl, Philipp Krausewitz, Sebastian Strieth, Glen Kristiansen, Markus Eckstein, Damian J Ralser, Michael Hölzel, Manuel Ritter, Jörg Ellinger, Dimo Dietrich, Niklas Klümper

  • Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.

    Histopathology

    Authors: Veronika Bahlinger, Annalena Branz, Pamela L Strissel, Reiner Strick, Fabienne Lange, Carol I Geppert, Niklas Klümper, Michael Hölzel, Sven Wach, Helge Taubert, Danijel Sikic, Bernd Wullich, Miriam Angeloni, Fulvia Ferrazzi, Lauri Diehl, Maria Kovalenko, Emon Elboudwarej, Juliane M Jürgensmeier, Arndt Hartmann, Markus Eckstein

  • Adipocyte precursor-derived NRG1 promotes resistance to FGFR inhibition in urothelial carcinoma.

    Cancer research

    Authors: Sana Hosni, Viola Kilian, Niklas Klümper, Daniela Gabbia, Katharina Sieckmann, Dillon Corvino, Anja Winkler, Miriam Saponaro, Karin Woersdoerfer, Doris Schmidt, Oliver Hahn, Ilaria Zanotto, Marina Bertlich, Marieta Toma, Tobias Bald, Markus Eckstein, Michael Hölzel, Matthias Geyer, Manuel Ritter, Dagmar Wachten, Sara De Martin, Abdullah Alajati

  • On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.

    European urology oncology

    Authors: Jonas Saal, Viktor Grünwald, Tobias Bald, Manuel Ritter, Peter Brossart, Yoshihiko Tomita, Arndt Hartmann, Michael Hölzel, Markus Eckstein, Niklas Klümper

  • Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors.

    Clinical & translational immunology

    Authors: Jonas Saal, Jörg Ellinger, Manuel Ritter, Peter Brossart, Michael Hölzel, Niklas Klümper, Tobias Bald